A New "Super Drug" Will Send This Biotech Stock Skyrocketing

One of the biggest waves in healthcare now is the care and treatment of the aging population. Among the more common maladies we face as we get older is arthritis - and specifically rheumatoid arthritis (RA). It's big deal, too. RA the third most common type of arthritis behind osteoarthritis and gout. And it affects over 1.3 million Americans and up to 1% of the world's population. Fortunately, a small biotech company revealed last week that, along with its partner, its new drug to help combat rheumatoid arthritis reached its test goals in its phase 3 study. The stage is now set for a "new drug application" for U.S. Food and Drug Administration approval. This drug has the potential to bring incredible gains for today's biotech stock... Tags: biotech stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post A New "Super Drug" Will Send This Biotech Stock Skyrocketing appeared first on Money Morning - We Make Investing Profitable .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.